Literature DB >> 1937767

Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

A B Hartman1, C J Powell, C L Schultz, E V Oaks, K H Eckels.   

Abstract

The development of a small-animal model to test the protective efficacy and immunogenicity of a vaccine strain against shigellosis would greatly facilitate the evaluation of potential vaccine candidates. In guinea pigs, the ability of shigellae to invade and multiply within the corneal epithelium, causing keratoconjunctivitis, closely mimics the invasion process in the intestinal epithelium (B. Sereny, Acta Microbiol. Acad. Sci. Hung. 4:367-376, 1957). The serum response of animals recovering from a Shigella keratoconjunctival infection was determined and found to be consistent with that shown by convalescent humans and primates. This model was used to test the efficacy of two vaccine candidates, and the immune response of the guinea pigs to the vaccine strains was examined. Both vaccine strains demonstrated significant protection against challenge by homologous virulent Shigella strains, and the results were comparable with results obtained in trials with monkeys. The guinea pig model also provides a rapid and inexpensive means of evaluating different immunization regimens as well as of testing other variables such as length of protection against disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1937767      PMCID: PMC258999          DOI: 10.1128/iai.59.11.4075-4083.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment.

Authors:  A R HIGGINS; T M FLOYD; M A KADER
Journal:  Am J Trop Med Hyg       Date:  1955-03       Impact factor: 2.345

2.  The use of the guinea-pig conjunctivae as an experimental model for the study of virulence of Shigella organisms.

Authors:  D C MACKEL; L F LANGLEY; L A VENICE
Journal:  Am J Hyg       Date:  1961-03

3.  Characterization of invasion plasmid antigen genes (ipaBCD) from Shigella flexneri.

Authors:  M M Venkatesan; J M Buysse; D J Kopecko
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection.

Authors:  H L DuPont; R B Hornick; M J Snyder; J P Libonati; S B Formal; E J Gangarosa
Journal:  J Infect Dis       Date:  1972-01       Impact factor: 5.226

5.  Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines.

Authors:  D M Mel; B L Arsić; B D Nikolić; M L Radovanić
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

6.  Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

Authors:  D Cohen; M S Green; C Block; T Rouach; I Ofek
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

7.  Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati).

Authors:  T Meitert; E Pencu; L Ciudin; M Tonciu
Journal:  Arch Roum Pathol Exp Microbiol       Date:  1984 Jul-Dec

8.  Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes.

Authors:  N K Verma; A A Lindberg
Journal:  Vaccine       Date:  1991-01       Impact factor: 3.641

9.  Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei.

Authors:  L Van de Verg; D A Herrington; J R Murphy; S S Wasserman; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

10.  Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen.

Authors:  S B Formal; T L Hale; C Kapfer; J P Cogan; P J Snoy; R Chung; M E Wingfield; B L Elisberg; L S Baron
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

View more
  30 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Authors:  R W Kaminski; M Wu; K R Turbyfill; K Clarkson; B Tai; A L Bourgeois; L L Van De Verg; R I Walker; E V Oaks
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

4.  Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Authors:  S R Klee; B D Tzschaschel; I Fält; A Kärnell; A A Lindberg; K N Timmis; C A Guzmán
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  An environmental Escherichia albertii strain, DM104, induces protective immunity to Shigella dysenteriae in guinea pig eye model.

Authors:  Fatema Moni Chowdhury; Mohammed Ziaur Rahman; Sirajul Islam Khan; Chowdhury Rafiqul Ahsan; Nils-Kåre Birkeland
Journal:  Curr Microbiol       Date:  2014-01-23       Impact factor: 2.188

6.  Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Authors:  K L Kotloff; D A Herrington; T L Hale; J W Newland; L Van De Verg; J P Cogan; P J Snoy; J C Sadoff; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

7.  Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a.

Authors:  A B Hartman; L L Van de Verg; C R Mainhart; B D Tall; S J Smith-Gill
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

8.  Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.

Authors:  M L Bernardini; J Arondel; I Martini; A Aidara; P J Sansonetti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

9.  Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.

Authors:  A B Hartman; M M Venkatesan
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

10.  Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Authors:  Ryan T Ranallo; Robert W Kaminski; Tonia George; Alexis A Kordis; Qing Chen; Kathleen Szabo; Malabi M Venkatesan
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.